Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease.
Screening is used to detect disease earlier in its course, allow earlier treatment, and presumably decrease morbidities and potential mortality associated with the later expression of more advanced disease and presumably more complex treatments consequently required. Judicious screening in bladder cancer depends on an understanding of how the different forms of bladder cancer express their biological potential, whether the tools available for screening have sufficient sensitivity and specificity to have accurate predictive value in accurately diagnosing and assessing each cancer diathesis earlier in its course, and how this may influence the morbidities and mortality associated with each. The principles of screening, potential biases that can affect their accuracy and the interpretation of outcomes, tools currently available for screening, their efficacies and pitfalls, and lessons learned from studies of the role of screening in prostate cancer will be reviewed to offer an understanding of the potential role that screening may play in the different forms of bladder cancer in the context of their preclinical and treated natural history.
Kakizoe
Tadao
T
National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. tkakizoe@ncc.go.jp
Mucci
Lorelei A
LA
Albertsen
Peter C
PC
Droller
Michael J
MJ
D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D014943:Global Health; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D008962:Models, Theoretical; D009017:Morbidity / Q000639:trends; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy